The purpose of the present study was to identify gene polymorphisms that confer susceptibility to recurrent restenosis after bare-metal stenting of coronary arteries, and thereby to assess the genetic risk for this condition. The study population comprised 527 unrelated Japanese individuals, including 28 subjects who developed in-stent restenosis two or more times and 499 subjects without reste...

The development of stent has been a major achievement in treating obstructive coronary artery disease (OCAD). The main obstacle in the long term success of percutaneous coronary intervention (PCI) was the neo-intimal hyperplasia developed within the stent, which may leads to instent restenosis. The introduction of Drug-eluting stents (DES) shows steep decrease in angiographic restenosis when co...

AIM To evaluate patterns of restenosis following implantation of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) in comparable unselected lesions. METHODS AND RESULTS We have identified all episodes of restenosis after SES or PES implantation in our institutions between March 2003 and March 2005. Restenosis pattern was classified as focal, diffuse, proliferative, or occlusive...

When performing percutaneous coronary revascularization, physicians nearly always supplement balloon angioplasty with a stent.1 This decision is based on evidence that stent implantation enhances the procedural success and durability of angioplasty. Benefits of stenting, compared with balloon angioplasty, include a reduction in the incidence of lesion recurrence, manifested as reduced need for ...

tion has been widely used for managing coronary artery occlusive disease. However, the risk of in-stent restenosis is about 10-40%, as determined on the angiographic follow-up at 6 months, and this remains a clinical issue in cardiology (1-3). Early identification of in-stent restenosis is important to reduce the number of recurrent ischemic episodes and to prevent myocardial infarction, thereb...

In-stent restenosis (ISR) is an adverse event of percutaneous coronary intervention (PCI) procedures [1]. Drugeluting stents (DES) have been shown to reduce the incidence of ISR to around 5% in contrast to bare metal stents (BMS), which have a 25% incidence. Patients with ISR may present with recurrence of anginal symptoms or an acute ischemic event and may need further PCI or bypass surgery [2...

BACKGROUND The effects of endovascular irradiation on uninjured reference segments during the treatment of in-stent restenosis are unknown. METHODS AND RESULTS In the Washington Radiation for In-Stent restenosis Trial (WRIST), patients with in-stent restenosis were first treated with conventional catheter-based techniques and then randomized (blinded) to receive either gamma-irradiation ((192...

Background—Treatment of in-stent restenosis with paclitaxel-coated balloon catheter as compared with plain balloon angioplasty has shown surprisingly low late lumen loss at 6 months and fewer major adverse cardiac events up to 2 years. We compared the efficacy and safety of a paclitaxel-coated balloon with a paclitaxel-eluting stent as the current standard of care. Methods and Results—One hundr...

OBJECTIVES We sought to determine the basis for restenosis within superficial femoral arteries (SFAs) and hemodialysis conduits treated with balloon-expandable stents. BACKGROUND Use of stents within coronary and peripheral vessels continues to increase exponentially. The mechanism of restenosis within stents placed at various vascular sites is not well understood. In particular, the implicat...

BACKGROUND Restenosis after implantation of drug-eluting stents (DES) is a rare phenomenon, occurring more frequently peri-stent. METHODS AND RESULTS We evaluated the pattern of restenosis occurring after implantation of DES in unselected lesions. From April 15 to December 6, 2002, we treated 368 patients with 735 lesions by using 841 rapamycin-eluting stents (Cypher, Cordis, a Johnson & John...